| mRNA |
GSK525762A |
CTRPv2 |
pan-cancer |
AAC |
0.0051 |
0.9 |
| mRNA |
cediranib |
CTRPv2 |
pan-cancer |
AAC |
-0.0089 |
0.9 |
| mRNA |
CAL-101 |
GDSC1000 |
pan-cancer |
AAC |
0.0052 |
0.9 |
| mRNA |
MLN4924 |
GDSC1000 |
pan-cancer |
AAC |
0.0066 |
0.9 |
| mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
-0.0055 |
0.9 |
| mRNA |
CP724714 |
GDSC1000 |
pan-cancer |
AAC |
0.0053 |
0.9 |
| mRNA |
T0901317 |
GDSC1000 |
pan-cancer |
AAC |
-0.0052 |
0.9 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0059 |
0.9 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0049 |
0.9 |
| mRNA |
Bortezomib |
FIMM |
pan-cancer |
AAC |
0.023 |
0.9 |